{"id":915664,"date":"2025-12-03T10:26:52","date_gmt":"2025-12-03T15:26:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"modified":"2025-12-03T10:26:52","modified_gmt":"2025-12-03T15:26:52","slug":"pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","title":{"rendered":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BRISBANE, Calif., Dec.  03, 2025  (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira\u2019s Amended and Restated 2014 Inducement Plan (the \u201cInducement Plan\u201d) as a material inducement to each employee\u2019s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People &amp; Compensation Committee of the Board of Directors (the \u201cCommittee\u201d) without stockholder approval.<\/p>\n<p>Two employees received restricted stock units for an aggregate of 2,200 shares of Pacira common stock. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on December 1, 2026.<\/p>\n<p>Vesting of the equity awards is subject to the employee\u2019s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.<\/p>\n<p>\n        <strong>About Pacira<\/strong>\n      <\/p>\n<p>Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL<sup>\u00ae<\/sup> (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA<sup>\u00ae<\/sup> (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera<sub>\u00ae<\/sub>\u00ba, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: bottom\">\n            <strong>Investor Contact:<\/strong><br \/>\n            <br \/>Susan Mesco, (973) 451-4030<br \/>susan.mesco@pacira.com<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\n            <strong>Media Contact:<\/strong><br \/>\n            <br \/>Sara Marino, (973) 370-5430<br \/>sara.marino@pacira.com<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjExNDZiZmYtY2Q4Ni00YTZlLTkyM2ItNWQ4N2Y1Y2I3NGM5LTEwMjA0ODQtMjAyNS0xMi0wMy1lbg==\/tiny\/Pacira-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira\u2019s Amended and Restated 2014 Inducement Plan (the \u201cInducement Plan\u201d) as a material inducement to each employee\u2019s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People &amp; Compensation Committee of the Board of Directors (the \u201cCommittee\u201d) without stockholder approval. Two employees received restricted stock units for an aggregate of 2,200 shares of Pacira common stock. Each restricted stock unit represents the contingent right &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915664","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira\u2019s Amended and Restated 2014 Inducement Plan (the \u201cInducement Plan\u201d) as a material inducement to each employee\u2019s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People &amp; Compensation Committee of the Board of Directors (the \u201cCommittee\u201d) without stockholder approval. Two employees received restricted stock units for an aggregate of 2,200 shares of Pacira common stock. Each restricted stock unit represents the contingent right &hellip; Continue reading &quot;Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T15:26:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2025-12-03T15:26:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"},\"wordCount\":337,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\",\"name\":\"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=\",\"datePublished\":\"2025-12-03T15:26:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","og_locale":"en_US","og_type":"article","og_title":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira\u2019s Amended and Restated 2014 Inducement Plan (the \u201cInducement Plan\u201d) as a material inducement to each employee\u2019s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People &amp; Compensation Committee of the Board of Directors (the \u201cCommittee\u201d) without stockholder approval. Two employees received restricted stock units for an aggregate of 2,200 shares of Pacira common stock. Each restricted stock unit represents the contingent right &hellip; Continue reading \"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T15:26:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2025-12-03T15:26:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"},"wordCount":337,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/","name":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=","datePublished":"2025-12-03T15:26:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NDU0NiM3Mjk5NDUzIzIwMDg5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915664"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915664\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}